Immune-mediated liver diseases: Programmed cell death ligands and circulating apoptotic markers

Expert Review of Molecular Diagnostics

Volumn 9, Issue 2, 2009, Pages 139-156

  Kremer, Andreas E ^a   Rust, Christian ^b   Eichhorn, Peter ^c   Beuers, Ulrich ^d   Holdenrieder, Stefan ^c  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY OF MUNICH   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Apoptosis; Autoimmune hepatitis; Cell death; Ligand; Liver; Primary biliary cirrhosis; Primary sclerosing cholangitis

Indexed keywords

CASPASE; CD14 ANTIGEN; CYTOKERATIN; FAS ANTIGEN; FAS LIGAND; GAMMA INTERFERON; GLOBULIN; GRANZYME B; MACROPHAGE MIGRATION INHIBITION FACTOR; NATURAL KILLER CELL RECEPTOR NKG2D; TISSUE POLYPEPTIDE ANTIGEN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; BIOLOGICAL MARKER;

APOPTOSIS; AUTOIMMUNE HEPATITIS; BILIARY CIRRHOSIS; CLINICAL FEATURE; DIAGNOSTIC PROCEDURE; HUMAN; NUCLEOSOME; PRIMARY SCLEROSING CHOLANGITIS; REVIEW; AUTOIMMUNE DISEASE; BLOOD; IMMUNOLOGY; LIVER DISEASE; METHODOLOGY; MONITORING;

APOPTOSIS; AUTOIMMUNE DISEASES; BIOLOGICAL MARKERS; HUMANS; LIVER DISEASES; MONITORING, PHYSIOLOGIC;

EID: 66549101781     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.9.2.139     Document Type: Review

References (213)

1. Rust C, Beuers U. Overlap syndromes among autoimmune liver diseases. World J. Gastroenterol. 14(21), 3368-3373 (2008).
2. Lleo A, Invernizzi P, Mackay IR, Prince H, Zhong RQ, Gershwin ME. Etiopathogenesis of primary biliary cirrhosis. World J. Gastroenterol. 14(21), 3328-3337 (2008).
3. Levy C, Lindor KD. Primary sclerosing cholangitis: epidemiology, natural history, and prognosis. Semin. Liver Dis. 26(1), 22-30 (2006).
4. Krawitt EL. Autoimmune hepatitis. N. Engl. J. Med. 354(1), 54-66 (2006).
5. Krawitt EL. Clinical features and management of autoimmune hepatitis. World J. Gastroenterol. 14(21), 3301-3305 (2008).
6. Rust C, Beuers U. Medical treatment of primary biliary cirrhosis and primary sclerosing cholangitis. Clin. Rev. Allergy Immunol. 28(2), 135-145 (2005).
7. Crosignani A, Battezzati PM, Invernizzi P, Selmi C, Prina E, Podda M. Clinical features and management of primary biliary cirrhosis. World J. Gastroenterol. 14(21), 3313-3327 (2008).
8. Paumgartner G, Pusl T. Medical treatment of cholestatic liver disease. Clin. Liver Dis. 12(1), 53-80 (2008).
9. Rust C, Beuers U. Medical treatment of primary biliary cirrhosis and primary sclerosing cholangitis. Clin. Rev. Allergy Immunol. 28(2), 135-146 (2005).
10. Gershwin ME, Selmi C, Worman HJ et al. Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview- based study of 1032 patients. Hepatology 42(5), 1194-1202 (2005).
11. Rieger R, Leung PS, Jeddeloh MR et al. Identification of 2-nonynoic acid, a cosmetic component, as a potential trigger of primary biliary cirrhosis. J. Autoimmun. 27(1), 7-16 (2006).
12. Crosignani A, Battezzati PM, Invernizzi P, Selmi C, Prina E, Podda M. Clinical features and management of primary biliary cirrhosis. World J. Gastroenterol. 14(21), 3313-3327 (2008).
13. Selmi C, Gershwin ME, Lindor KD et al. Quality of life and everyday activities in patients with primary biliary cirrhosis. Hepatology 46(6), 1836-1843 (2007).
14. Kremer AE, Beuers U, Oude-Elferink RP, Pusl T. Pathogenesis and treatment of pruritus in cholestasis. Drugs 68(15), 2163-2182 (2008).
15. Lee YM, Kaplan MM. Primary sclerosing cholangitis. N. Engl. J. Med. 332(14), 924-933 (1995).
16. Silveira MG, Lindor KD. Clinical features and management of primary sclerosing cholangitis. World J. Gastroenterol. 14(21), 3338-3349 (2008).
17. Kaplan GG, Laupland KB, Butzner D, Urbanski SJ, Lee SS. The burden of large and small duct primary sclerosing cholangitis in adults and children: a population-based analysis. Am. J. Gastroenterol. 102(5), 1042-1049 (2007).
18. Krawitt EL. Clinical features and management of autoimmune hepatitis. World J. Gastroenterol. 14(21), 3301-3305 (2008).
19. Abe M, Onji M, Kawai-Ninomiya K et al. Clinicopathologic features of the severe form of acute type 1 autoimmune hepatitis. Clin. Gastroenterol Hepatol. 5(2), 255-258 (2007).
20. Prince MI, Chetwynd A, Craig WL, Metcalf JV, James OF. Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom progression in a large population based cohort. Gut 53(6), 865-870 (2004).
21. Vierling JM. Primary biliary cirrhosis and autoimmune cholangiopathy. Clin. Liver Dis. 8(1), 177-194 (2004).
22. Wesierska-Gadek J, Klima A, Komina O, Ranftler C, Invernizzi P, Penner E. Characterization of autoantibodies against components of the nuclear pore complexes: high frequency of anti-p62 nucleoporin antibodies. Ann. NY Acad. Sci. 1109, 519-530 (2007).
23. Wesierska-Gadek J, Penner E, Battezzati PM et al. Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis. Hepatology 43(5), 1135-1144 (2006).
24. LaRusso NF, Shneider BL, Black D et al. Primary sclerosing cholangitis: summary of a workshop. Hepatology 44(3), 746-764 (2006).
25. Poupon R, Chazouilleres O, Poupon RE. Chronic cholestatic diseases. J. Hepatol. 32(1 Suppl.), 129-140 (2000).
26. Chapman R, Cullen S. Etiopathogenesis of primary sclerosing cholangitis. World J. Gastroenterol. 14(21), 3350-3359 (2008).
27. Alvarez F, Berg PA, Bianchi FB et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J. Hepatol. 31(5), 929-938 (1999).
28. Hennes EM, Zeniya M, Czaja AJ et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 48(1), 169-176 (2008).
29. Mackay IR. Autoimmune disease overlaps and the liver: two for the price of one? J. Gastroenterol. Hepatol. 15(1), 3-8 (2000).
30. Czaja AJ, Cassani F, Cataleta M, Valentini P, Bianchi FB. Frequency and significance of antibodies to actin in type 1 autoimmune hepatitis. Hepatology 24(5), 1068-1073 (1996).
31. Wies I, Brunner S, Henninger J et al. Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis. Lancet 355(9214), 1510-1515 (2000).
32. Baeres M, Herkel J, Czaja AJ et al. Establishment of standardised SLA/LP immunoassays: specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics. Gut 51(2), 259-264 (2002).
33. Bogdanos DP, Invernizzi P, Mackay IR, Vergani D. Autoimmune liver serology: current diagnostic and clinical challenges. World J. Gastroenterol. 14(21), 3374-3387 (2008).
34. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br. J. Cancer 26(4), 239-257 (1972).
35. Wyllie AH, Kerr JF, Currie AR. Cell death: the significance of apoptosis. Int. Rev. Cytol. 68, 251-306 (1980).
36. Bellamy CO, Malcomson RD, Harrison DJ, Wyllie AH. Cell death in health and disease: the biology and regulation of apoptosis. Semin. Cancer Biol. 6(1), 3-16 (1995).
37. Cohen JJ. Apoptosis. Immunol. Today 14(3), 126-130 (1993).
38. Ren Y, Savill J. Apoptosis: the importance of being eaten. Cell. Death Differ. 5(7), 563-568 (1998).
39. Jahr S, Hentze H, Englisch S et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 61(4), 1659-1665 (2001).
40. Lichtenstein AV, Melkonyan HS, Tomei LD, Umansky SR. Circulating nucleic acids and apoptosis. Ann. NY Acad. Sci. 945, 239-249 (2001).
41. Trejo-Becerril C, Perez-Cardenas E, Trevino-Cuevas H et al. Circulating nucleosomes and response to chemotherapy: an in vitro, in vivo and clinical study on cervical cancer patients. Int. J. Cancer 104(6), 663-668 (2003).
42. Kerr JF, Winterford CM, Harmon BV. Apoptosis. Its significance in cancer and cancer therapy. Cancer 73(8), 2013-2026 (1994).
43. Darzynkiewicz Z, Juan G, Li X, Gorczyca W, Murakami T, Traganos F. Cytometry in cell necrobiology: analysis of apoptosis and accidental cell death (necrosis). Cytometry 27(1), 1-20 (1997).
44. Okada H, Mak TW. Pathways of apoptotic and non-apoptotic death in tumour cells. Nat. Rev. Cancer 4(8), 592-603 (2004).
45. Leist M, Single B, Castoldi AF, Kuhnle S, Nicotera P. Intracellular adenosine triphosphate (ATP) concentration: a switch in the decision between apoptosis and necrosis. J. Exp. Med. 185(8), 1481-1486 (1997).
46. Formigli L, Papucci L, Tani A et al. Aponecrosis: morphological and biochemical exploration of a syncretic process of cell death sharing apoptosis and necrosis. J. Cell. Physiol. 182(1), 41-49 (2000).
47. Leist M, Jaattela M. Four deaths and a funeral: from caspases to alternative mechanisms. Nat. Rev. Mol. Cell. Biol. 2(8), 589-598 (2001).
48. Degterev A, Huang Z, Boyce M et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat. Chem. Biol. 1(2), 112-119 (2005).
49. Kelekar A. Autophagy. Ann. NY Acad. Sci. 1066, 259-271 (2005).
50. Hengartner MO. The biochemistry of apoptosis. Nature 407(6805), 770-776 (2000).
51. Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged sword. Nat. Rev. Immunol. 3(9), 745-756 (2003).
52. Fadeel B, Orrenius S. Apoptosis: a basic biological phenomenon with wide-ranging implications in human disease. J. Intern. Med. 258(6), 479-517 (2005).
53. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science 281(5381), 1305-1308 (1998).
54. Krammer PH. CD95's deadly mission in the immune system. Nature 407(6805), 789-795 (2000).
55. Medema JP, Scaffidi C, Kischkel FC et al. FLICE is activated by association with the CD95 death-inducing signaling complex (DISC). Embo. J. 16(10), 2794-2804 (1997).
56. Strasser A. The role of BH3-only proteins in the immune system. Nat. Rev. Immunol. 5(3), 189-200 (2005).
57. Siegel RM. Caspases at the crossroads of immune-cell life and death. Nat. Rev. Immunol. 6(4), 308-317 (2006).
58. Holdenrieder S, Stieber P. Apoptotic markers in cancer. Clin. Biochem. 37(7), 605-617 (2004).
59. Sartorius U, Schmitz I, Krammer PH. Molecular mechanisms of death-receptor- mediated apoptosis. Chembiochemistry 2(1), 20-29 (2001).
60. Thornberry NA, Lazebnik Y. Caspases: enemies within. Science 281(5381), 1312-1316 (1998).
61. Sheard MA, Vojtesek B, Simickova M, Valik D. Release of cytokeratin-18 and -19 fragments (TPS and CYFRA 21-1) into the extracellular space during apoptosis. J. Cell. Biochem. 85(4), 670-677 (2002).
62. Enari M, Sakahira H, Yokoyama H, Okawa K, Iwamatsu A, Nagata S. A caspase- activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature 391(6662), 43-50 (1998).
63. Susin SA, Lorenzo HK, Zamzami N et al. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 397(6718), 441-446 (1999).
64. Joza N, Susin SA, Daugas E et al. Essential role of the mitochondrial apoptosis-inducing factor in programmed cell death. Nature 410(6828), 549-554 (2001).
65. Tschopp J, Irmler M, Thome M. Inhibition of fas death signals by FLIPs. Curr. Opin. Immunol. 10(5), 552-558 (1998).
66. Kroemer G. The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nat. Med. 3(6), 614-620 (1997).
67. Adams J, Cory S. The Bcl-2 protein familiy: arbiters of cell survival. Science 281(5381), 1322-1326 (1998).
68. Roy N, Deveraux QL, Takahashi R, Salvesen GS, Reed JC. The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases. Embo. J. 16(23), 6914-6925 (1997).
69. Deveraux QL, Stennicke HR, Salvesen GS, Reed JC. Endogenous inhibitors of caspases. J. Clin. Immunol. 19(6), 388-398 (1999).
70. Du C, Fang M, Li Y, Li L, Wang X. Smac, a m itochondrial protein that promotes cytochrome C-dependent caspase activation by eliminating IAP inhibition. Cell 102(1), 33-42 (2000).
71. Verhagen AM, Ekert PG, Pakusch M et al. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 102(1), 43-53 (2000).
72. van Loo G, van Gurp M, Depuydt B et al. The serine protease Omi/HtrA2 is released from mitochondria during apoptosis. Omi interacts with caspase- inhibitor XIAP and induces enhanced caspase activity. Cell Death Differ. 9 (1), 20-26 (2002).
73. Natoli G, Costanzo A, Guido F, Moretti F, Levrero M. Apoptotic, non-apoptotic, and anti-apoptotic pathways of tumor necrosis factor signalling. Biochem. Pharmacol. 56(8), 915-920 (1998).
74. Chen G, Goeddel DV. TNF-R1 signaling: a beautiful pathway. Science 296(5573), 1634-1635 (2002).
75. Heldin CH, Miyazono K, ten Dijke P. TGF-p signalling from cell membrane to nucleus through SMAD proteins. Nature 390(6659), 465-471 (1997).
76. Perlman R, Schiemann WP, Brooks MW, Lodish HF, Weinberg RA. TGF-p- induced apoptosis is mediated by the adapter protein Daxx that facilitates JNK activation. Nat. Cell Biol. 3(8), 708-714 (2001).
77. Archbold JK, Ely LK, Kjer-Nielsen L et al. T cell allorecognition and MHC restriction - a case of Jekyll and Hyde? Mol. Immunol. 45(3), 583-598 (2008).
78. Henkart PA. Lymphocyte-mediated cytotoxicity: two pathways and multiple effector molecules. Immunity 1(5), 343-346 (1994).
79. Catalfamo M, Henkart PA. Perforin and the granule exocytosis cytotoxicity pathway. Curr. Opin. Immunol. 15 (5), 522-527 (2003).
80. Froelich CJ, Orth K, Turbov J et al. New paradigm for lymphocyte granule- mediated cytotoxicity. Target cells bind and internalize granzyme B, but an endosomolytic agent is necessary for cytosolic delivery and subsequent apoptosis. J. Biol. Chem. 271(46), 29073-29079 (1996).
81. MacDonald G, Shi L, Vande Velde C, Lieberman J, Greenberg AH. Mitochondria-dependent and -independent regulation of granzyme B-induced apoptosis. J. Exp. Med. 189(1), 131-144 (1999).
82. Lord SJ, Rajotte RV, Korbutt GS, Bleackley RC. Granzyme B: a natural born killer. Immunol. Rev. 193, 31-38 (2003).
83. Sionov RV, Haupt Y. The cellular response to p53: the decision between life and death. Oncogene 18(45), 6145-6157 (1999).
84. Christen U, von Herrath MG. Induction, acceleration or prevention of autoimmunity by molecular mimicry. Mol. Immunol. 40(14-15), 1113-1120 (2004).
85. Leung PS, Park O, Tsuneyama K et al. Induction of primary biliary cirrhosis in guinea pigs following chemical xenobiotic immunization. J. Immunol. 179(4), 2651-2657 (2007).
86. Carroll MC. The lupus paradox. Nat. Genet. 19(1), 3-4 (1998).
87. Lauber K, Blumenthal SG, Waibel M, Wesselborg S. Clearance of apoptotic cells: getting rid of the corpses. Mol. Cell 14(3), 277-287 (2004).
88. Lleo A, Selmi C, Invernizzi P, Podda M, Gershwin ME. The consequences of apoptosis in autoimmunity. J. Autoimmun. 31(3), 257-262(2008).
89. Gershwin ME, Mackay IR, Sturgess A, Coppel RL. Identification and specificity of a cDNA encoding the 70 kd mitochondrial antigen recognized in primary biliary cirrhosis. J. Immunol. 138(10), 3525 -3531 (1987).
90. Dubel L, Tanaka A, Leung PS et al. Autoepitope mapping and reactivity of autoantibodies to the dihydrolipoamide dehydrogenase-binding protein (E3BP) and the glycine cleavage proteins in primary biliary cirrhosis. Hepatology 29(4), 1013-1018 (1999).
91. Gershwin ME, Ansari AA, Mackay IR et al. Primary biliary cirrhosis: an orchestrated immune response against epithelial cells. Immunol. Rev. 174, 210-225 (2000).
92. Kita H, Matsumura S, He XS et al. Quantitative and functional analysis of PDC-E2-specific autoreactive cytotoxic T lymphocytes in primary biliary cirrhosis. J. Clin. Invest. 109(9), 1231-1240 (2002).
93. Shimoda S, Ishikawa F, Kamihira T et al. Autoreactive T-cell responses in primary biliary cirrhosis are proinflammatory whereas those of controls are regulatory. Gastroenterology 131(2), 606-618 (2006).
94. Gershwin ME, Mackay IR. The causes of primary biliary cirrhosis: convenient and inconvenient truths. Hepatology 47(2), 737-745 (2008).
95. Harada K, Ozaki S, Gershwin ME, Nakanuma Y. Enhanced apoptosis relates to bile duct loss in primary biliary cirrhosis. Hepatology 26(6), 1399-1405 (1997).
96. Allina J, Hu B, Sullivan DM et al. T cell targeting and phagocytosis of apoptotic biliary epithelial cells in primary biliary cirrhosis. J. Autoimmun. 27(4), 232-241 (2006).
97. Salunga TL, Cui ZG, Shimoda S et al. Oxidative stress-induced apoptosis of bile duct cells in primary biliary cirrhosis. J. Autoimmun. 29(2-3), 78-86 (2007).
98. Van de Water J, Gerson LB, Ferrell LD et al. Immunohistochemical evidence of disease recurrence after liver transplantation for primary biliary cirrhosis. Hepatology. 24(5), 1079-1084 (1996).
99. Lleo A, Invernizzi P, Selmi C et al. Autophagy: highlighting a novel player in the autoimmunity scenario. J. Autoimmun. 29(2-3), 61-68 (2007).
100. Odin JA, Huebert RC, Casciola-Rosen L, LaRusso NF, Rosen A. Bcl-2-dependent oxidation of pyruvate dehydrogenase-E2, a primary biliary cirrhosis autoantigen, during apoptosis. J. Clin. Invest. 108(2), 223-232 (2001).
101. Allina J, Stanca CM, Garber J et al. Anti-CD16 autoantibodies and delayed phagocytosis of apoptotic cells in primary biliary cirrhosis. J. Autoimmun. 30(4), 238-245 (2008).
102. Roos A, Xu W, Castellano G et al. Mini-review: a pivotal role for innate immunity in the clearance of apoptotic cells. Eur J. Immunol. 34(4), 921-929 (2004).
103. Koga H, Sakisaka S, Ohishi M, Sata M, Tanikawa K. Nuclear DNA fragmentation and expression of Bcl-2 in primary biliary cirrhosis. Hepatology 25(5), 1077-1084 (1997).
104. Beuers U. Drug insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Nat. Clin. Pract. Gastroenterol. Hepatol. 3(6), 318-328 (2006).
105. Saarinen S, Olerup O, Broome U. Increased frequency of autoimmune diseases in patients with primary sclerosing cholangitis. Am. J. Gastroenterol. 95(11), 3195-3199 (2000).
106. Angulo P, Peter JB, Gershwin ME et al. Serum autoantibodies in patients with primary sclerosing cholangitis. J. Hepatol. 32(2), 182-187 (2000).
107. Worthington J, Cullen S, Chapman R. Immunopathogenesis of primary sclerosing cholangitis. Clin. Rev. Allergy Immunol. 28(2), 93-103 (2005).
108. Adams DH, Eksteen B. Aberrant homing of mucosal T cells and extra-intestinal manifestations of inflammatory bowel disease. Nat. Rev. Immunol. 6(3), 244-251 (2006).
109. Maggs JR, Chapman RW. An update on primary sclerosing cholangitis. Curr Opin Gastroenterol. 24(3), 377-383 (2008).
110. Sheth P, Delos Santos N, Seth A, LaRusso NF, Rao RK. Lipopolysaccharide disrupts tight junctions in cholangiocyte monolayers by a c-Src-, TLR4-, and LBP-dependent mechanism. Am. J. Physiol. Gastrointest. Liver Physiol. 293(1), G308-G318 (2007).
111. Karrar A, Broome U, Sodergren T et al. Biliary epithelial cell antibodies link adaptive and innate immune responses in primary sclerosing cholangitis. Gastroenterology 132(4), 1504-1514 (2007).
112. Elferink RO. Cholestasis. Gut 52(Suppl. 2), II42-II48 (2003).
113. Javitt NB. Cholestasis in rats induced by taurolithocholate. Nature 210(5042), 1262-1263 (1966).
114. Schmucker DL, Ohta M, Kanai S, Sato Y, Kitani K. Hepatic injury induced by bile salts: correlation between biochemical and morphological events. Hepatology 12(5), 1216-1221 (1990).
115. Benz C, Angermuller S, Otto G, Sauer P, Stremmel W, Stiehl A. Effect of tauroursodeoxycholic acid on bile acid-induced apoptosis in primary human hepatocytes. Eur. J. Clin. Invest. 30(3), 203-209 (2000).
116. Rodrigues CM, Fan G, Ma X, Kren BT, Steer CJ. A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation. J. Clin. Invest. 101(12), 2790-2799 (1998).
117. Graf D, Kurz AK, Fischer R, Reinehr R, Haussinger D. Taurolithocholic acid-3 sulfate induces CD95 trafficking and apoptosis in a c-Jun N-terminal kinase- dependent manner. Gastroenterology 122(5), 1411-1427 (2002).
118. Beuers U, Spengler U, Zwiebel FM, Pauletzki J, Fischer S, Paumgartner G. Effect of ursodeoxycholic acid on the kinetics of the major hydrophobic bile acids in health and in chronic cholestatic liver disease. Hepatology 15(4), 603-608 (1992).
119. Hofmann AF. Cholestatic liver disease: pathophysiology and therapeutic options. Liver 22(Suppl. 2), 14-19 (2002).
120. Patel T, Bronk SF, Gores GJ. Increases of intracellular magnesium promote glycodeoxycholate-induced apoptosis in rat hepatocytes. J. Clin. Invest. 94(6), 2183-2192 (1994).
121. Chieco P, Romagnoli E, Aicardi G, Suozzi A, Forti GC, Roda A. Apoptosis induced in rat hepatocytes by in vivo exposure to taurochenodeoxycholate. Histochem. J. 29(11-12), 875-883 (1997).
122. Spivey JR, Bronk SF, Gores GJ. Glycochenodeoxycholate-induced lethal hepatocellular injury in rat hepatocytes. Role of ATP depletion and cytosolic free calcium. J. Clin. Invest. 92(1), 17-24 (1993).
123. Patel T, Gores GJ. Apoptosis and hepatobiliary disease. Hepatology 21(6), 1725-1741 (1995).
124. Koga H, Sakisaka S, Ohishi M, Sata M, Tanikawa K. Nuclear DNA fragmentation and expression of Bcl-2 in primary biliary cirrhosis. Hepatology 25(5), 1077-1084 (1997).
125. Rust C, Wild N, Bernt C, Vennegeerts T, Wimmer R, Beuers U. Bile acid-induced apoptosis in hepatocytes is caspase-6- dependent. J. Biol. Chem. 284(5), 2908-2916 (2009).
126. Faubion WA, Guicciardi ME, Miyoshi H et al. Toxic bile salts induce rodent hepatocyte apoptosis via direct activation of Fas. J. Clin. Invest. 103(1), 137-145 (1999).
127. Reinehr R, Becker S, Wettstein M, Haussinger D. Involvement of the Src family kinase yes in bile salt-induced apoptosis. Gastroenterology 127(5), 1540-1557 (2004).
128. Reinehr R, Graf D, Haussinger D. Bile salt-induced hepatocyte apoptosis involves epidermal growth factor receptor-dependent CD95 tyrosine phosphorylation. Gastroenterology 125(3), 839-853 (2003).
129. Reinehr R, Haussinger D. Inhibition of bile salt-induced apoptosis by cyclic AMP involves serine/threonine phosphorylation of CD95. Gastroenterology 126(1), 249-262 (2004).
130. Reinehr R, Schliess F, Haussinger D. Hyperosmolarity and CD95L trigger CD95/EGF receptor association and tyrosine phosphorylation of CD95 as prerequisites for CD95 membrane trafficking and DISC formation. FASEB. J. 17(6), 731-733 (2003).
131. Higuchi H, Grambihler A, Canbay A, Bronk SF, Gores GJ. Bile acids up-regulate death receptor 5/TRAIL-receptor 2 expression via a c-Jun N-terminal kinase- dependent pathway involving Sp1. J. Biol. Chem. 279(1), 51-60 (2004).
132. Bernt C, Vennegeerts T, Beuers U, Rust C. The human transcription factor AP-1 is a mediator of bile acid-induced liver cell apoptosis. Biochem. Biophys. Res. Commun. 340(3), 800-806 (2006).
133. Stravitz RT, Rao YP, Vlahcevic ZR, Gurley EC, Jarvis WD, Hylemon PB. Hepatocellular protein kinase C activation by bile acids: implications for regulation of cholesterol 7 a-hydroxylase. Am. J. Physiol. 271(2 Pt 1), G293-G303 (1996).
134. Jones BA, Rao YP, Stravitz RT, Gores GJ. Bile salt-induced apoptosis of hepatocytes involves activation of protein kinase C. Am. J. Physiol. 272(5 Pt 1), G1109-G1115 (1997).
135. Roberts LR, Kurosawa H, Bronk SF et al. Cathepsin B contributes to bile salt-induced apoptosis of rat hepatocytes. Gastroenterology 113(5), 1714-1726 (1997).
136. Canbay A, Guicciardi ME, Higuchi H et al. Cathepsin B inactivation attenuates hepatic injury and fibrosis during cholestasis. J. Clin. Invest. 112(2), 152-159 (2003).
137. Sokol RJ, Winklhofer-Roob BM, Devereaux MW, McKim JM Jr. Generation of hydroperoxides in isolated rat hepatocytes and hepatic mitochondria exposed to hydrophobic bile acids. Gastroenterology 109(4), 1249-1256 (1995).
138. Sokol RJ, Dahl R, Devereaux MW, Yerushalmi B, Kobak GE, Gumpricht E. Human hepatic mitochondria generate reactive oxygen species and undergo the permeability transition in response to hydrophobic bile acids. J. Pediatr. Gastroenterol. Nutr. 41(2), 235-243 (2005).
139. Krahenbuhl S, Talos C, Fischer S, Reichen J. Toxicity of bile acids on the electron transport chain of isolated rat liver mitochondria. Hepatology 19(2), 471-479 (1994).
140. Botla R, Spivey JR, Aguilar H, Bronk SF, Gores GJ. Ursodeoxycholate (UDCA) inhibits the mitochondrial membrane permeability transition induced by glycochenodeoxycholate: a mechanism of UDCA cytoprotection. J. Pharm. Exp. Ther. 272(2), 930-938 (1995).
141. Lemasters JJ, Nieminen AL, Qian T et al. The mitochondrial permeability transition in cell death: a common mechanism in necrosis, apoptosis and autophagy. Biochim. Biophys. Acta 1366(1-2), 177-196 (1998).
142. Patel T, Gores GJ. Inhibition of bile-salt- induced hepatocyte apoptosis by the antioxidant lazaroid U83836E. Toxicol. Appl. Pharmacol. 142(1), 116-122 (1997).
143. Sokol RJ, McKim JM Jr, Goff MC et al. Vitamin E reduces oxidant injury to mitochondria and the hepatotoxicity of tau rochenodeoxycholic acid in the rat. Gastroenterology 114(1), 164-174 (1998).
144. Gumpricht E, Dahl R, Devereaux MW, Sokol RJ. B-carotene prevents bile acid-induced cytotoxicity in the rat hepatocyte: evidence for an antioxidant and anti-apoptotic role of p-carotene in vitro. Pediatr. Res. 55(5), 814-821 (2004).
145. Ru st C, Bauchmuller K, Bernt C et al. Sulfasalazine reduces bile acid induced apoptosis in human hepatoma cells and perfused rat livers. Gut 55(5), 719-727 (2006).
146. Bernstein H, Payne CM, Bernstein C, Schneider J, Beard SE, Crowley CL. Activation of the promoters of genes associated with DNA damage, oxidative stress, ER stress and protein malfolding by the bile salt, deoxycholate. Toxicol. Lett. 108(1), 37-46 (1999).
147. Xie Q, Khaoustov VI, Chung CC et al. Effect of tauroursodeoxycholic acid on endoplasmic reticulum stress-induced caspase-12 activation. Hepatology 36(3), 592-601 (2002).
148. Tsuchiya S, Tsuji M, Morio Y, Oguchi K. Involvement of endoplasmic reticulum in glycochenodeoxycholic acid-induced apoptosis in rat hepatocytes. Toxicol. Lett. 166(2), 140-149 (2006).
149. Nakagawa T, Zhu H, Morishima N et al. Caspase-12 mediates endoplasmic- reticulum-specific apoptosis and cytotoxicity by amyloid-p. Nature 403(6765), 98-103 (2000).
150. Iizaka T, Tsuji M, Oyamada H, Morio Y, Oguchi K. Interaction between caspase-8 activation and endoplasmic reticulum stress in glycochenodeoxycholic acid- induced apoptotic HepG2 cells. Toxicolog y 241(3), 146-156 (2007).
151. Rust C, Karnitz LM, Paya CV, Moscat J, Simari RD, Gores GJ. The bile acid tau rochenodeoxycholate activates a phosphatidylinositol 3-kinase-dependent survival signaling cascade. J. Biol. Chem. 275(26), 20210-20216 (2000).
152. Takikawa Y, Miyoshi H, Rust C et al. The bile acid-activated phosphatidylinositol 3 -kinase pathway inhibits Fas apoptosis upstream of bid in rodent hepatocytes. Gastroenterology 120(7), 1810 -1817 (2001).
153. Webster CR, Anwer MS. Phosphoinositide 3 -kinase, but not mitogen-activated protein kinase, pathway is involved in hepatocyte growth factor-mediated protection against bile acid-induced apoptosis in cultured rat hepatocytes. Hepatology 33(3), 608-615 (2001).
154. Kurz AK, Block C, Graf D, Dahl SV, Schliess F, Haussinger D. Phosphoinositide 3-kinase-dependent Ras activation by tauroursodesoxycholate in rat liver. Biochem J. 350(Pt 1), 207-213 (2000).
155. Miyoshi H, Rust C, Guicciardi ME, Gores GJ. NF-kB is activated in cholestasis and functions to reduce liver injury. Am. J. Pathol. 158(3), 967-975 (2001).
156. Paumgartner G, Beuers U. Mechanisms of action and therapeutic efficacy of ursodeoxycholic acid in cholestatic liver disease. Clin. Liver Dis. 8(1), 67-81 (2004).
157. Masuichi H, Seki S, Kitada T et al. Significant role of apoptosis in type-1 autoimmune hepatitis. Osaka City Med. J. 45(1), 61-79 (1999).
158. Ogawa S, Sakaguchi K, Takaki A et al. Increase in CD95 (Fas/APO-1)-positive CD4+ and CD8+ T cells in peripheral blood derived from patients with autoimmune hepatitis or chronic hepatitis C with autoimmune phenomena. J. Gastroenterol. Hepatol. 15(1), 69-75 (2000).
159. Fox CK, Furtwaengler A, Nepomuceno RR, Martinez OM, Krams SM. Apoptotic pathways in primary biliary cirrhosis and autoimmune hepatitis. Liver 21(4), 272-279 (2001).
160. Bayer EM, Herr W, Kanzler S et al. Transforming growth factor-p1 in autoimmune hepatitis: correlation of liver tissue expression and serum levels with disease activity. J. Hepatol. 28(5), 803-811 (1998).
161. + T cells in the liver. J. Immunol. 172(9), 5222-5229 (2004).
162. Lapierre P, Beland K, Alvarez F. Pathogenesis of autoimmune hepatitis: from break of tolerance to immune- mediated hepatocyte apoptosis. Transl. Res. 149(3), 107-113 (2007).
163. Salih HR, Holdenrieder S, Steinle A. Soluble NKG2D ligands: prevalence, release, and functional impact. Front. Biosci. 13, 3448-3456 (2008).
164. + regulatory T-cells in autoimmune liver disease. J. Hepatol. 41(1), 31-37 (2004).
165. Longhi MS, Ma Y, Mitry RR et al. Effect of CD4+ CD25 + regulatory T-cells on CD8 T-cell function in patients with autoimmune hepatitis. J. Autoimmun. 25(1), 63-71 (2005).
166. Longhi MS, Meda F, Wang P et al. Expansion and de novo generation of potentially therapeutic regulatory T cells in patients with autoimmune hepatitis. Hepatology 47(2), 581-591 (2008).
167. Seki S, Kitada T, Iwai S et al. Immunohistochemical detection of Fas and apoptosis in type-1 autoimmune hepatitis. Hepatogastroenterology 50(53), 1274-1277 (2003).
168. Ward TH, Cummings J, Dean E et al. Biomarkers of apoptosis. Br. J. Cancer 99(6), 841-846 (2008).
169. Beachy SH, Repasky EA. Using extracellular biomarkers for monitoring efficacy of therapeutics in cancer patients: an update. Cancer Immunol. Immunother. 57(6), 759-775 (2008).
170. Bai J, Odin JA. Apoptosis and the liver: relation to autoimmunity and related conditions. Autoimmun. Rev. 2(1), 36-42 (2003).
171. Hengartner MO. Apoptosis: corralling the corpses. Cell 104(3), 325-328 (2001).
172. van der Vaart M, Pretorius PJ. Circulating DNA. Its origin and fluctuation. Ann. NY Acad. Sci. 1137, 18-26 (2008).
173. Holdenrieder S, Nagel D, Schalhorn A et al. Clinical relevance of circulating nucleosomes in cancer. Ann. NY Acad. Sci. 1137, 180-189 (2008).
174. Berg CP, Stein GM, Keppeler H, Gregor M, Wesselborg S, Lauber K. Apoptosis- associated antigens recognized by autoantibodies in patients with the autoimmune liver disease primary biliary cirrhosis. Apoptosis 13(1), 63-75 (2008).
175. Tortorella C, Sacco R, Orlando P, Salerno MT, Schiraldi O, Antonaci S. sICAM-1, sCD95 and sCD95L levels in chronic liver diseases of different etiology. Immunopharmacol. Immunotoxicol. 22(1), 19-33 (2000).
176. Pelli N, Floreani A, Torre F et al. Soluble apoptosis molecules in primary biliary cirrhosis: analysis and commitment of the Fas and tumour necrosis factor-related apoptosis-inducing ligand systems in comparison with chronic hepatitis C. Clin. Exp. Immunol. 148(1), 85-89 (2007).
177. Liang Y, Yang Z, Li C, Zhu Y, Zhang L, Zhong R. Characterisation of TNF-related apoptosis-inducing ligand in peripheral blood in patients with primary biliary cirrhosis. Clin. Exp. Med. 8(1), 1-7 (2008).
178. Tsikrikoni A, Kyriakou DS, Rigopoulou EI et al. Markers of cell activation and apoptosis in bone marrow mononuclear cells of patients with autoimmune hepatitis type 1 and primary biliary cirrhosis. J. Hepatol. 42(3), 393-399 (2005).
179. Yagmur E, Trautwein C, Leers MP, Gressner AM, Tacke F. Elevated apoptosis-associated cytokeratin 18 fragments (CK18Asp386) in serum of patients with chronic liver diseases indicate hepatic and biliary inflammation. Clin. Biochem. 40(9-10), 651-655 (2007).
180. Yilmaz Y, Dolar E, Ulukaya E et al. Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis. WorldJ. Gastroenterol. 13(6), 837-844 (2007).
181. Younossi ZM, Jarrar M, Nugent C et al. A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH). Obes. Surg. 18(11), 1430-1437 (2008).
182. Luft T, Conzelmann M, Benner A et al. Serum cytokeratin-18 fragments as quantitative markers of epithelial apoptosis in liver and intestinal graft-versus-host disease. Blood 110(13), 4535-4542 (2007).
183. Hetz H, Hoetzenecker K, Hacker S et al. Caspase-cleaved cytokeratin 18 and 20 S proteasome in liver degeneration. J. Clin. Lab. Anal. 21(5), 277-281 (2007).
184. Gonzalez-Quintela A, Mallo N, Mella C et al. Serum levels of cytokeratin-18 (tissue polypeptide-specific antigen) in liver diseases. Liver Int. 26(10), 1217-1224 (2006).
185. Holdenrieder S, Eichhorn P, Beuers U et al. Nucleosomal DNA fragments in autoimmune diseases. Ann. NY Acad. Sci. 1075, 318-327 (2006).
186. Thomson AW, Satoh S, Nussler AK et al. Circulating intercellular adhesion molecule-1 (ICAM-1) in autoimmune liver disease and evidence for the production of ICAM-1 by cytokine-stimulated human hepatocytes. Clin. Exp. Immunol. 95(1), 83-90 (1994).
187. Santos LL, Morand EF. The role of macrophage migration inhibitory factor in the inflammatory immune response and rheumatoid arthritis. Wien. Med. Wochenschr. 156(1-2), 11-18 (2006).
188. Mizue Y, Nishihira J, Miyazaki T et al. Quantitation of macrophage migration inhibitory factor (MIF) using the one-step sandwich enzyme immunosorbent assay: elevated serum MIF concentrations in patients with autoimmune diseases and identification of MIF in erythrocytes. Int. J. Mol. Med. 5(4), 397-403 (2000).
189. Morand EF, Leech M. Macrophage migration inhibitory factor in rheumatoid arthritis. Front. Biosci. 10, 12-22 (2005).
190. Stosic-Grujicic S, Stojanovic I, Maksimovic- Ivanic D et al. Macrophage migration inhibitory factor (MIF) is necessary for progression of autoimmune diabetes mellitus. J. Cell. Physiol. 215(3), 665-675 (2008).
191. Hoi AY, Morand EF, Leech M. Is macrophage migration inhibitory factor a therapeutic target in systemic lupus erythematosus? Immunol. Cell Biol. 81(5), 367-373 (2003).
192. Foote A, Briganti EM, Kipen Y, Santos L, Leech M, Morand EF. Macrophage migration inhibitory factor in systemic lupus erythematosus. J. Rheumatol. 31(2), 268-273 (2004).
193. Zou YQ, Lu LJ, Li SJ et al. The levels of macrophage migration inhibitory factor as an indicator of disease activity and severity in adult-onset Still's disease. Clin. Biochem. 41(7-8), 519-524 (2008).
194. Willeke P, Gaubitz M, Schotte H et al. Increased serum levels of macrophage migration inhibitory factor in patients with primary Sjogren's syndrome. Arthritis Res. Ther. 9(2), R43 (2007).
195. Chuang CC, Wang ST, Chen WC, Chen CC, Hor LI, Chuang AY. Increases in serum macrophage migration inhibitory factor in patients with severe sepsis predict early mortality. Shock 27(5), 503-506 (2007).
196. Weigand MA, Horner C, Bardenheuer HJ, Bouchon A. The systemic inflammatory response syndrome. Best Pract. Res. Clin. Anaesthesiol. 18(3), 455-475 (2004).
197. Zernecke A, Bernhagen J, Weber C. Macrophage migration inhibitory factor in cardiovascular disease. Circulation 117(12), 1594-1602 (2008).
198. Krockenberger M, Dombrowski Y, Weidler C et al. Macrophage migration inhibitory factor contributes to the immune escape of ovarian cancer by down-regulating NKG2D. J. Immunol. 180(11), 7338-7348 (2008).
199. He XX, Yang J, Ding YW, Liu W, Shen QY, Xia HH. Increased epithelial and serum expression of macrophage migration inhibitory factor (MIF) in gastric cancer: potential role of MIF in gastric carcinogenesis. Gut 55(6), 797-802 (2006).
200. Baumann R, Casaulta C, Simon D, Conus S, Yousefi S, Simon HU. Macrophage migration inhibitory factor delays apoptosis in neutrophils by inhibiting the mitochondria-dependent death pathway. FASEB J. 17(15), 2221-2230 (2003).
201. Damico RL, Chesley A, Johnston L et al. Macrophage migration inhibitory factor governs endothelial cell sensitivity to LPS-induced apoptosis. Am. J. Respir. Cell. Mol. Biol. 39(1), 77-85 (2008).
202. Leech M, Lacey D, Xue JR et al. Regulation of p53 by macrophage migration inhibitory factor in inflammatory arthritis. Arthritis Rheum. 48(7), 1881-1889 (2003).
203. Ogasawara K, Hamerman JA, Ehrlich LR et al. NKG2D blockade prevents autoimmune diabetes in NOD mice. Immunity 20(6), 757-767 (2004).
204. Ogasawara K, Lanier LL. NKG2D in NK and T cell-mediated immunity. J. Clin. Immunol. 25(6), 534-540 (2005).
205. Caillat-Zucman S. How NKG2D ligands trigger autoimmunity? Hum. Immunol. 67(3), 204-207 (2006).
206. Groh V, Bruhl A, El-Gabalawy H, Nelson JL, Spies T. Stimulation of T cell autoreactivity by anomalous expression of NKG2D and its MIC ligands in rheumatoid arthritis. Proc. Natl Acad. Sci. USA 100(16), 9452-9457 (2003).
207. Holdenrieder S, Eichhorn P, Beuers U et al. Soluble NKG2D ligands in hepatic autoimmune diseases and in benign diseases involved in marker metabolism. Anticancer Res. 27(4A), 2041-2045 (2007).
208. Oikawa T, Takahashi H, Ishikawa T et al. Intrahepatic expression of the co-stimulatory molecules programmed death-1, and its ligands in autoimmune liver disease. Pathol. Int. 57(8), 485-492 (2007).
209. + T lymphocytes. Immunity 20(3), 327-336 (2004).
210. Mataki N, Kikuchi K, Kawai T et al. Expression of PD-1, PD-L1, and PD-L2 in the liver in autoimmune liver diseases. Am. J. Gastroenterol. 102(2), 302-312 (2007).
211. Holdenrieder S, Stieber P, Peterfi A, Nagel D, Steinle A, Salih HR. Soluble MICA in malignant diseases. Int. J. Cancer 118(3), 684-687 (2006).
212. Holdenrieder S, Stieber P, Peterfi A, Nagel D, Steinle A, Salih HR. Soluble MICB in malignant diseases: analysis of diagnostic significance and correlation with soluble MICA. Cancer Immunol. Immunother. 55(12), 1584-1589 (2006).
213. Beuers U, Rust C. Overlap syndromes. Semin. LiverDis. 25(3), 311-320 (2005).